drugset / Trial / NCT06493552
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEphB4-HSA containing regimen is safe and whether the oncological endpoints of importance in each cohort improve as a result of treatment with sEphB4-HSA containing regimen relative to a predefined threshold or to a control arm in the cohort where available. Treatment continues until progression of disease or unacceptable toxicities arise.
Timeline
- Start
- 2025-03-15
- Primary completion
- 2029-09
- Completion
- 2034-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Enfortumab Vedotin | Other / unclassified | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | sEphB4-HSA | Protein / enzyme biologic | 10 mg/kg | Intravenous |